Skip to main content

Table 2 Study population characteristics (CCMP patients)

From: Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure

Total n = 19

Age (yrs) Mean (SD)

57.8 ± 12.4

Male, n (%)

6 (31.6)

Race, n (%)

 Caucasian

9 (47.4)

 Black

6 (31.6)

 Hispanic

4 (21)

BMI Mean (SD)

28.5 ± 6.9

Comorbidities n (%)

 Diabetes

7 (36.8)

 Hypertension

13 (68.4)

 Hyperlipidemia

4 (21)

 CAD

3 (15.8)

 CKD

5 (26.3)

 COPD

3 (15.8)

 Tobacco

3 (15.8)

 Obesity

6 (31.6)

Diagnosis, n (%)

 Breast Cancer

8 (42.1)

 Hematologic

7 (36.8)

  Non-Hodgkin Lymphoma

3 (42.9)

  Hodgkin Lymphoma

2 (28.6)

  DLBCL

1 (14.3)

  AML

1 (14.3)

 Other

4 (21)

Treatment

 Anthracycline-based chemotherapy

8 (42.1)

 Radiation

2 (10.5)

 Anthracycline-based chemotherapy plus radiation

9 (47.4)